3. Skyrizi

Skyrizi's annual maintenance price of $59,000, before rebates and discounts, "is lower than the most widely prescribed biologic treatments for moderate to severe plaque psoriasis,” a spokeswoman said via email after its approval. (AbbVie)

Generic name: risankizumab-rzaa
Company: AbbVie
Disease: psoriasis
2024 sales estimate: $2.1 billion 

How do you break into a market as crowded as the next-generation psoriasis field? Come armed with data that might just be best-in-class. At least, that’s what AbbVie’s Skyrizi did, analysts figure.

RELATED: In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst

The psoriasis newcomer grabbed the FDA’s favor in April, joining Johnson & Johnson’s Tremfya and Sun’s Ilumya in the IL-23 class. And it won that nod on the back of a trove of positive data. Skyrizi “should benefit from … best-in-category efficacy,” SVB Leerink analyst Geoffrey Porges wrote to clients at the time, pointing to “stellar” phase 3 results that showed Skyrizi could clear skin lesions by 90% in up to three-quarters of patients within a week.

AbbVie isn’t just relying on the numbers to get the job done, though. It also boasts a convenience boost over its J&J rival, which requires maintenance doses every eight weeks. After initial Skyrizi doses at the outset and four weeks later, patients on the AbbVie drug only require four doses per year.

RELATED: AbbVie shakes up psoriasis field with blockbuster-to-be newcomer Skyrizi

The Illinois drugmaker is also hoping its pricing strategy will help dent Tremfya’s market share. It put an $88,500 first-year sticker on the drug to reflect the two starter doses, and that list price drops to $59,000 down the line. The annual maintenance price "is lower than the most widely prescribed biologic treatments for moderate to severe plaque psoriasis,” a spokeswoman wrote by email shortly after approval.

The drug also has plenty of prospects beyond psoriasis. It’s currently in phase 3 testing as a treatment for Crohn’s disease, ulcerative colitis and psoriatic arthritis.

Thing is, so are many of its competitors outside the IL-23 world. In addition to Tremfya and Ilumya, Skyrizi is also up against the IL-17s—Novartis’ Cosentyx, Eli Lilly’s Taltz and Valeant’s Siliq—as well as IL-12/23 drug Stelara from J&J, Celgene psoriasis pill Otezla, and the class of anti-TNF giants, led by AbbVie’s Humira.

3. Skyrizi